These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15746079)

  • 1. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
    Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
    Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
    Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
    Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
    Chan PM; Ilangumaran S; La Rose J; Chakrabartty A; Rottapel R
    Mol Cell Biol; 2003 May; 23(9):3067-78. PubMed ID: 12697809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
    Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
    Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
    Jin Y; Ding K; Wang D; Shen M; Pan J
    Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
    Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
    Lindblad O; Kazi JU; Rönnstrand L; Sun J
    Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
    Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
    Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
    Jin Y; Chen Q; Shi X; Lu Z; Cheng C; Lai Y; Zheng Q; Pan J
    Cancer Sci; 2009 Jul; 100(7):1335-43. PubMed ID: 19383029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
    Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
    Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.